Community/Retail

Pharmacist-led interventions significantly improve antibiotic prescribing practices, optimize therapy, and improve patient outcomes.

High-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B did not have significant correlations with chronic obstructive pulmonary disease.

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

Identifying drug-related problems is a vital component of medication therapy management.

The cobas liat system is a closed system that aims to reduce contamination risks and enhances the reliability of results at the point of care.

Antiviral treatments for respiratory viruses such as respiratory syncytial virus (RSV) are crucial, especially with the rise of the "triple-demic."

Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.

Approximately 66% of patients received a COVID-19 vaccine in the fall of 2024 and only 26% received a respiratory syncytial virus vaccine.

Remission is a new emphasis and treatment goal for the management of asthma.

As medication experts, pharmacists can aid in treatment selection and support patients through the process.

Glucose monitoring can help providers and pharmacists optimize medication management for personalized diabetes care.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Pharmacists can play an important role in tobacco cessation.

The US health care market faces transformative changes in 2025, as biosimilars, GLP-1s, and new pharmacy economics reshape how benefit managers balance innovation with affordability.

Ruling potentially affects federal ability to regulate pharmacy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

Patients recovering from COVID-19 and caregivers reported how some social determinants of health were helpful in their recovery, while others led to difficult social and mental challenges.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The Commission aims to provide information for clinical decision making, therapeutic interventions, and public health strategies.

Despite these findings, navacaprant was generally well-tolerated and safe in patients with major depressive disorder.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patient-centered care involves educating and empowering individuals to take responsibility for their own care.

Biotin supplementation could mitigate manganese-induced damage caused by manganese deficiency and excessive exposure.

Approximately 33.2% of patients who received semaglutide 7.2 mg achieved 25% or more weight loss after 72 weeks.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.

The caps on insulin and yearly out-of-pocket drug costs remain unaffected by this decision.

Engaging with the community, providing transparent information to patients, and using noncoercive methods of encouragement are strategies to reduce COVID-19 vaccine hesitancy.